Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb; R-Pharm
• Treatments: Capecitabine

Criteria

Inclusion Criteria:

• Recovery from surgery or radiation therapy

• Measurable or non-measurable disease

• Available for follow-up

Exclusion Criteria:

• Neuropathy

• Uncontrolled pulmonary or cardiovascular disease

• Known history of HIV infection